• Benign Prostatic Hyperplasia
  • Hormone Therapy
  • Genomic Testing
  • Next-Generation Imaging
  • UTUC
  • OAB and Incontinence
  • Genitourinary Cancers
  • Kidney Cancer
  • Men's Health
  • Pediatrics
  • Female Urology
  • Sexual Dysfunction
  • Kidney Stones
  • Urologic Surgery
  • Bladder Cancer
  • Benign Conditions
  • Prostate Cancer

Nerve stimulation device may be alternative to OAB drug therapy

Article

A minimally invasive form of nerve stimulation appears to be an effective alternative to drug therapy in patients with overactive bladder, study results show.

A minimally invasive form of nerve stimulation appears to be an effective alternative to drug therapy in patients with overactive bladder, study results show.

The 12-week, randomized, multicenter study compared anticholinergic drug therapy with percutaneous tibial nerve stimulation (PTNS [Urgent PC System, Uroplasty, Inc., Minnetonka, MN]), an office-based treatment. Study results, which appear in the Journal of Urology (2009; 182:1055-61), include the following:

80% of PTNS patients considered their OAB symptoms cured or improved, while 55% of patients receiving extended-release tolterodine (Detrol LA) considered themselves cured or improved.

Physicians considered 80% of PTNS patients cured or improved, compared with 61% of extended-release tolterodine patients.

The frequency of voiding episodes was reduced in 73% of PTNS patients versus 74% of extended-release tolterodine patients.

80% of PTNS patients had an improvement in urge incontinence compared to 73% of extended-release tolterodine patients.

"PTNS may be considered a clinically significant alternative to pharmacologic therapy for the treatment of OAB with statistically significant improvements in patient self-assessments compared with drugs, and comparable objective effectiveness," said lead author Kenneth M. Peters, MD, of Beaumont Hospital in Royal Oak, MI. "PTNS represents an important addition to our therapeutic armamentarium."

The research was supported by Uroplasty. Some of the study authors have disclosed financial interest or other relationships with Uroplasty, Medtronic, Allergan, Pfizer, Astellas, Watson, and/or Novartis.

Related Videos
Gary D. Steinberg, MD, an expert on bladder cancer
Akhil Das, MD, FACS, answers a question during a video interview
Edward M. Schaeffer, MD, PhD, answers a question during a Zoom video interview
Woman talking with doctor | Image Credit: © rocketclips - stock.adobe.com
Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
Gamal M. Ghoniem, MD, FACS, ABU/FPMRS, gives an answer during a video interview
Related Content
© 2024 MJH Life Sciences

All rights reserved.